apo e(130-149) mimetic peptide

Apo e(130-149) mimetic peptide is a synthetic peptide derived from amino acids 130–149 of the low-density lipoprotein (LDL) receptor-binding domain of apolipoprotein E (apoE). It is designed to mimic the functional receptor-binding region of native apoE, specifically the amphipathic helix important for receptor interaction. This peptide can bind to apoE cell surface receptors—such as LDLR and LRP-1—and retain functional activity similar to the full-length protein. It has demonstrated potent anti-inflammatory, neuroprotective, and barrier-stabilizing effects in preclinical models, including reduction of pro-inflammatory cytokines (TNF, IL-6) and blood-brain barrier (BBB) disruption after brain injury. The mechanism involves modulation of inflammatory signaling cascades (such as the CypA-NF-κB-MMP-9 pathway), positive modulation of protein phosphatase 2A (PP2A) activity via SET binding antagonism, and suppression of neuronal cell apoptosis. The peptide has been investigated in mouse models for conditions including brain injury, subarachnoid hemorrhage, blood-brain barrier dysfunction, and experimental asthma via LDLR-dependent pathways[1][2][3]. It remains in preclinical or early clinical development.

Other names

apoE mimetic peptideapomimetic peptideapoE-derived peptideapolipoprotein-derived peptide